VOTING AGREEMENTVoting Agreement • October 6th, 2020 • KKR Genetic Disorder L.P. • Pharmaceutical preparations • Delaware
THIS VOTING AGREEMENT, dated as of October 5, 2020 (this “Agreement”), is between Eidos Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the parties listed on Schedule A hereto (each, a “Stockholder” and, collectively, the “Stockholders”).
JOINT FILING AGREEMENTJoint Filing Agreement • July 10th, 2019 • KKR Genetic Disorder L.P. • Pharmaceutical preparations
This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of shares of Common Stock, $0.001 par value per share, of BridgeBio Pharma Inc., is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below that is named as a reporting person in such filing in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • September 17th, 2024 • KKR Genetic Disorder L.P. • Pharmaceutical preparations
This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of shares of Common Stock, $0.001 par value per share, of BridgeBio Pharma, Inc. is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below that is named as a reporting person in such filing in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
BridgeBio Pharma LLC Lock-Up Agreement February 13, 2019Lock-Up Agreement • July 10th, 2019 • KKR Genetic Disorder L.P. • Pharmaceutical preparations
JOINT FILING AGREEMENTJoint Filing Agreement • June 1st, 2020 • KKR Genetic Disorder L.P. • Pharmaceutical preparations
This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of shares of Common Stock, $0.001 par value per share, of BridgeBio Pharma Inc., is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below that is named as a reporting person in such filing in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
BridgeBio Pharma, Inc. Lock-Up Agreement February 11, 2021Lock-Up Agreement • February 17th, 2021 • KKR Genetic Disorder L.P. • Pharmaceutical preparations
